Discuss This ICD-10 Code Read Blog Posts

ICD-10: E71.518

Other disorders of peroxisome biogenesis

Additional Information

Description

The ICD-10 code E71.518 refers to "Other disorders of peroxisome biogenesis." This classification falls under the broader category of disorders related to peroxisome biogenesis, which are critical for various metabolic processes in the body.

Overview of Peroxisome Biogenesis Disorders

Peroxisomes are small, membrane-bound organelles found in the cytoplasm of eukaryotic cells. They play a vital role in lipid metabolism, including the breakdown of very long-chain fatty acids, and are involved in the detoxification of hydrogen peroxide and other reactive oxygen species. Disorders of peroxisome biogenesis can lead to a range of metabolic dysfunctions, often resulting in severe neurological and developmental issues.

Clinical Features

Patients with disorders of peroxisome biogenesis may present with a variety of symptoms, which can include:

  • Neurological Impairments: Developmental delays, intellectual disability, and seizures are common due to the role of peroxisomes in brain metabolism.
  • Dysmorphic Features: Some patients may exhibit characteristic facial features or skeletal abnormalities.
  • Liver Dysfunction: Hepatomegaly (enlarged liver) and liver dysfunction can occur due to impaired lipid metabolism.
  • Vision and Hearing Loss: Retinal degeneration and hearing impairment may also be observed.
  • Hypotonia: Reduced muscle tone is frequently noted in affected individuals.

Types of Disorders

The term "Other disorders of peroxisome biogenesis" encompasses various specific conditions that do not fall under the more commonly recognized peroxisomal disorders, such as Zellweger syndrome, X-linked adrenoleukodystrophy, and infantile Refsum disease. These conditions may have overlapping symptoms but differ in their genetic causes and specific metabolic disruptions.

Genetic Basis

Most peroxisome biogenesis disorders are inherited in an autosomal recessive manner, meaning that both copies of the gene in each cell have mutations. The genes involved are typically related to the formation and function of peroxisomes, and mutations can lead to a complete or partial loss of peroxisome function.

Diagnosis

Diagnosis of disorders related to peroxisome biogenesis often involves:

  • Clinical Evaluation: Assessment of symptoms and family history.
  • Biochemical Testing: Measurement of very long-chain fatty acids and other metabolites in blood or urine.
  • Genetic Testing: Identification of mutations in genes associated with peroxisome biogenesis.

Management and Treatment

Currently, there is no cure for disorders of peroxisome biogenesis. Management focuses on supportive care, which may include:

  • Nutritional Support: Special diets may be recommended to manage metabolic imbalances.
  • Physical and Occupational Therapy: To address developmental delays and improve quality of life.
  • Symptomatic Treatment: Medications may be prescribed to manage specific symptoms, such as seizures.

Conclusion

ICD-10 code E71.518 captures a complex group of disorders that arise from defects in peroxisome biogenesis. These conditions can lead to significant health challenges, particularly affecting neurological development and metabolic function. Early diagnosis and supportive management are crucial for improving outcomes for affected individuals. As research continues, advancements in genetic therapies may offer hope for more effective treatments in the future.

Approximate Synonyms

ICD-10 code E71.518 refers to "Other disorders of peroxisome biogenesis." This classification encompasses a range of genetic disorders that affect the formation and function of peroxisomes, which are essential organelles involved in various metabolic processes, including lipid metabolism and the detoxification of harmful substances.

  1. Peroxisomal Biogenesis Disorders (PBDs): This is a broader category that includes various conditions resulting from defects in peroxisome formation and function.

  2. Zellweger Spectrum Disorders (ZSD): This term encompasses a group of disorders that vary in severity, including Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile refsum disease, all of which are linked to peroxisome biogenesis defects.

  3. Single Peroxisomal Biogenesis Disorders: Specific disorders within the spectrum may be referred to by their individual names, such as:
    - Zellweger Syndrome: The most severe form, characterized by multiple organ dysfunction and developmental delays.
    - Neonatal Adrenoleukodystrophy: A milder form that typically presents in infancy with neurological symptoms.
    - Infantile Refsum Disease: A rare disorder that leads to neurological and visual impairments.

  4. Peroxisome Assembly Disorders: This term may be used interchangeably to describe conditions that involve the improper assembly of peroxisomes.

  5. Disorders of Peroxisomal Metabolism: While this term is broader, it can include conditions related to peroxisome dysfunction, including those caused by biogenesis issues.

  6. Genetic Disorders of Peroxisome Function: This phrase highlights the genetic basis of these disorders, emphasizing their hereditary nature.

  • Peroxisomal Disorders: A general term that includes all types of disorders affecting peroxisome function, including those not strictly related to biogenesis.
  • Metabolic Disorders: Since peroxisomes play a crucial role in metabolism, these disorders can also be classified under metabolic disorders.
  • Lipid Metabolism Disorders: Given the role of peroxisomes in lipid metabolism, some conditions may be categorized under this term.

Conclusion

Understanding the alternative names and related terms for ICD-10 code E71.518 is essential for accurate diagnosis, treatment, and research into these complex genetic disorders. The terminology reflects the diverse manifestations and underlying genetic causes of peroxisome biogenesis disorders, which can significantly impact patient care and management strategies.

Diagnostic Criteria

The ICD-10 code E71.518 refers to "Other disorders of peroxisome biogenesis," which encompasses a range of genetic conditions that affect the formation and function of peroxisomes—cellular organelles involved in various metabolic processes, including lipid metabolism and the detoxification of harmful substances. Diagnosing disorders associated with this code involves a combination of clinical evaluation, laboratory tests, and genetic analysis.

Diagnostic Criteria for E71.518

Clinical Evaluation

  1. Patient History: A thorough medical history is essential, focusing on developmental milestones, neurological symptoms, and any metabolic disturbances. Symptoms may include:
    - Developmental delays
    - Neurological deficits
    - Hypotonia (decreased muscle tone)
    - Vision and hearing impairments

  2. Physical Examination: A comprehensive physical examination may reveal characteristic features associated with peroxisomal disorders, such as:
    - Dysmorphic features
    - Hepatomegaly (enlarged liver)
    - Renal anomalies
    - Skin manifestations

Laboratory Tests

  1. Biochemical Testing: Specific metabolic tests can help identify abnormalities in fatty acid metabolism, including:
    - Elevated very long-chain fatty acids (VLCFAs) in plasma or tissue samples.
    - Abnormal levels of phytanic acid or pristanic acid.

  2. Imaging Studies: MRI or CT scans may be utilized to assess brain structure and identify any abnormalities, such as white matter changes or other neurological findings.

Genetic Testing

  1. Molecular Genetic Testing: Genetic testing is crucial for confirming a diagnosis of peroxisome biogenesis disorders. This may involve:
    - Sequencing of genes associated with peroxisome biogenesis, such as PEX genes (e.g., PEX1, PEX6).
    - Identification of pathogenic variants that correlate with clinical symptoms.

  2. Family History: Since many peroxisomal disorders are inherited in an autosomal recessive manner, obtaining a detailed family history can provide insights into potential genetic predispositions.

Differential Diagnosis

It is important to differentiate E71.518 from other metabolic disorders that may present with similar symptoms. Conditions such as mitochondrial disorders, lysosomal storage diseases, and other genetic syndromes should be considered during the diagnostic process.

Conclusion

The diagnosis of disorders classified under ICD-10 code E71.518 requires a multidisciplinary approach, integrating clinical assessment, biochemical analysis, and genetic testing. Early diagnosis is crucial for managing symptoms and providing appropriate interventions, as these disorders can significantly impact the quality of life and developmental outcomes for affected individuals. If you suspect a peroxisomal disorder, consulting with a specialist in metabolic or genetic disorders is recommended for comprehensive evaluation and management.

Treatment Guidelines

Disorders of peroxisome biogenesis, classified under ICD-10 code E71.518, encompass a range of genetic conditions that affect the formation and function of peroxisomes, which are essential organelles involved in various metabolic processes, including lipid metabolism and the detoxification of reactive oxygen species. The most notable disorder in this category is Zellweger syndrome, but other related conditions also exist. Here, we will explore standard treatment approaches for these disorders.

Overview of Peroxisome Biogenesis Disorders

Peroxisome biogenesis disorders (PBDs) are typically caused by mutations in genes responsible for the formation and maintenance of peroxisomes. These disorders can lead to a variety of symptoms, including developmental delays, neurological issues, liver dysfunction, and metabolic disturbances. The severity and specific symptoms can vary widely among individuals, making diagnosis and treatment complex.

Standard Treatment Approaches

1. Symptomatic Management

Given the complexity and variability of symptoms associated with PBDs, treatment is primarily symptomatic and supportive. This may include:

  • Nutritional Support: Patients may require specialized diets to manage metabolic imbalances. For instance, a diet low in very long-chain fatty acids (VLCFAs) may be recommended, as these can accumulate in individuals with PBDs due to impaired metabolism[1].
  • Physical and Occupational Therapy: These therapies can help improve motor skills and daily functioning, particularly in children who may experience developmental delays[2].
  • Speech Therapy: For patients with communication difficulties, speech therapy can be beneficial in enhancing language skills and social interaction[3].

2. Medications

While there is no cure for PBDs, certain medications may help manage specific symptoms:

  • Anticonvulsants: If seizures are present, anticonvulsant medications may be prescribed to control seizure activity[4].
  • Hormonal Treatments: In some cases, hormone replacement therapy may be indicated, particularly if adrenal insufficiency is a concern[5].

3. Genetic Counseling

Genetic counseling is crucial for families affected by PBDs. It provides information about the inheritance patterns, risks for future pregnancies, and available genetic testing options. This can help families make informed decisions regarding family planning and management of the condition[6].

4. Research and Experimental Therapies

Ongoing research is exploring potential therapies aimed at correcting the underlying genetic defects or enhancing peroxisome function. While these are not standard treatments yet, they hold promise for future management strategies:

  • Gene Therapy: Investigational approaches are being studied to deliver functional copies of the defective genes responsible for PBDs[7].
  • Enzyme Replacement Therapy: Similar to treatments for other metabolic disorders, this approach aims to provide the missing or deficient enzymes that peroxisomes typically produce[8].

Conclusion

The management of disorders of peroxisome biogenesis, such as those classified under ICD-10 code E71.518, is primarily supportive and symptomatic, focusing on improving quality of life and managing specific symptoms. As research progresses, new therapeutic options may emerge, offering hope for more effective treatments in the future. Families affected by these disorders should engage with healthcare providers for personalized management plans and consider genetic counseling for comprehensive support.

References

  1. Nutritional guidelines for metabolic disorders.
  2. Role of physical therapy in developmental disorders.
  3. Importance of speech therapy in developmental delays.
  4. Use of anticonvulsants in seizure management.
  5. Hormonal treatments for adrenal insufficiency.
  6. Genetic counseling for hereditary conditions.
  7. Advances in gene therapy for metabolic disorders.
  8. Potential of enzyme replacement therapy in metabolic diseases.

Related Information

Description

  • Disorders of peroxisome biogenesis
  • Critical for lipid metabolism and detoxification
  • Lead to metabolic dysfunctions and neurological issues
  • Symptoms include developmental delays and seizures
  • Impaired liver function and vision/hearing loss
  • Reduced muscle tone and dysmorphic features
  • Inherited in an autosomal recessive manner

Approximate Synonyms

  • Peroxisomal Biogenesis Disorders
  • Zellweger Spectrum Disorders
  • Single Peroxisomal Biogenesis Disorders
  • Peroxisome Assembly Disorders
  • Disorders of Peroxisomal Metabolism
  • Genetic Disorders of Peroxisome Function

Diagnostic Criteria

  • Thorough medical history required
  • Developmental delays common symptom
  • Neurological deficits present
  • Hypotonia often seen
  • Vision impairments noted
  • Hearing impairments documented
  • Dysmorphic features observed
  • Hepatomegaly identified
  • Renal anomalies found
  • Skin manifestations present
  • Elevated VLCFAs in plasma or tissue
  • Abnormal phytanic acid levels
  • Abnormal pristanic acid levels
  • MRI or CT scans used for imaging
  • Sequencing of PEX genes required
  • Pathogenic variants identified
  • Family history obtained
  • Differential diagnosis from other disorders

Treatment Guidelines

  • Nutritional Support: Specialized diet to manage VLCFAs
  • Physical Therapy: Improve motor skills and daily functioning
  • Speech Therapy: Enhance language skills and social interaction
  • Anticonvulsants: Control seizure activity if present
  • Hormonal Treatments: Manage adrenal insufficiency if necessary
  • Genetic Counseling: Provide information on inheritance patterns
  • Gene Therapy: Investigational approach to correct genetic defects

Related Diseases

Yunis-Varon syndrome XFE progeroid syndrome WHIM syndrome 1 Nance-Horan syndrome alpha-methylacyl-CoA racemase deficiency ulnar-mammary syndrome ethylmalonic encephalopathy dicarboxylic aminoaciduria lethal congenital contracture syndrome 3 Muenke Syndrome restrictive dermopathy autosomal recessive Robinow syndrome autosomal dominant Robinow syndrome 2 EEC syndrome hypomyelinating leukodystrophy 12 syndromic X-linked intellectual disability Lubs type syndromic X-linked intellectual disability 5 Prieto syndrome syndromic X-linked intellectual disability Hedera type syndromic X-linked intellectual disability 7 Wilson-Turner syndrome Miles-Carpenter syndrome syndromic X-linked intellectual disability Abidi type syndromic X-linked intellectual disability Chudley-Schwartz type Christianson syndrome obsolete Brooks-Wisniewski-Brown syndrome Griscelli syndrome type 1 Griscelli syndrome type 2 Griscelli syndrome type 3 hereditary neuropathy with liability to pressure palsies Norrie disease Warburg micro syndrome Van Maldergem syndrome UV-sensitive syndrome MASA syndrome Smith-McCort dysplasia Simpson-Golabi-Behmel syndrome type 1 dyschromatosis symmetrica hereditaria pontocerebellar hypoplasia type 1B pontocerebellar hypoplasia type 2A pontocerebellar hypoplasia type 2B pontocerebellar hypoplasia type 3 pontocerebellar hypoplasia type 4 pontocerebellar hypoplasia type 6 pontocerebellar hypoplasia type 10 peeling skin syndrome Ohdo syndrome Ohdo syndrome, SBBYS variant congenital secretory chloride diarrhea 1 Meier-Gorlin syndrome autosomal recessive intellectual developmental disorder Rapp-Hodgkin syndrome CEDNIK syndrome Native American myopathy acrorenal syndrome Stormorken syndrome Vici syndrome punctate palmoplantar keratoderma Galloway-Mowat syndrome 1 Hennekam syndrome orofaciodigital syndrome III orofaciodigital syndrome IV Joubert syndrome with orofaciodigital defect orofaciodigital syndrome VIII orofaciodigital syndrome XI acrofacial dysostosis Rodriguez type chondrodysplasia Blomstrand type chromosome 10q23 deletion syndrome chromosome 18p deletion syndrome chromosome 4q21 deletion syndrome chromosome 6q11-q14 deletion syndrome chromosome 16p11.2 duplication syndrome chromosome 17q12 duplication syndrome Cole-Carpenter syndrome lysinuric protein intolerance stromal dystrophy Schnyder corneal dystrophy chromosome 5p13 duplication syndrome Desbuquois dysplasia fibrochondrogenesis salt and pepper syndrome Kindler syndrome Goldberg-Shprintzen syndrome MEDNIK syndrome EAST syndrome Perry syndrome Pitt-Hopkins syndrome Schimke immuno-osseous dysplasia autoimmune neuropathy Warsaw breakage syndrome Barber-Say syndrome ablepharon macrostomia syndrome ataxia with oculomotor apraxia type 3 lethal congenital contracture syndrome 1 lethal congenital contracture syndrome 2 Char syndrome Holzgreve-Wagner-Rehder Syndrome Ritscher-Schinzel syndrome 1 Ritscher-Schinzel syndrome 2 3MC syndrome 1 3MC syndrome 2 3MC syndrome 3 spinocerebellar ataxia type 10 spinocerebellar ataxia type 12 spinocerebellar ataxia type 13 spinocerebellar ataxia type 17 spinocerebellar ataxia type 18 spinocerebellar ataxia type 19/22 spinocerebellar ataxia type 23 spinocerebellar ataxia type 27 spinocerebellar ataxia type 28 spinocerebellar ataxia type 30 spinocerebellar ataxia type 34 spinocerebellar ataxia type 35 spinocerebellar ataxia type 38 episodic ataxia type 3 episodic ataxia type 6 episodic ataxia type 8 autosomal recessive spinocerebellar ataxia 10 coronin-1A deficiency reticular dysgenesis Pearson syndrome delta chain disease akinetopsia Kennedy's disease juvenile absence epilepsy amyotrophic lateral sclerosis type 16 Cogan-Reese syndrome Adams-Oliver syndrome Baraitser-Winter syndrome Carpenter syndrome cranioectodermal dysplasia glycogen storage disease XV congenital generalized lipodystrophy ABCD syndrome Askin's tumor Aland Island eye disease Allan-Herndon-Dudley syndrome Finnish type amyloidosis anauxetic dysplasia 1 obsolete anonychia congenita Baller-Gerold syndrome Bamforth-Lazarus syndrome Bart-Pumphrey syndrome bestrophinopathy Bethlem myopathy Birk-Barel syndrome Bjornstad syndrome Blau syndrome Boomerang dysplasia Borjeson-Forssman-Lehmann syndrome Bowen-Conradi syndrome branchiooculofacial syndrome Brody myopathy Brooke-Spiegler syndrome Brown-Vialetto-Van Laere syndrome neonatal period electroclinical syndrome variable age at onset electroclinical syndrome AGAT deficiency COX deficiency, infantile mitochondrial myopathy vitamin metabolic disorder PSAT deficiency PSPH deficiency tyrosinemia type III methylmalonic aciduria and homocystinuria type cblE congenital intrinsic factor deficiency X-linked monogenic disease autosomal dominant disease Y-linked monogenic disease Qazi Markouizos syndrome deafness-dystonia-optic neuronopathy syndrome X-linked myopathy with excessive autophagy adenylosuccinase lyase deficiency ARC syndrome spastic ataxia 1 rapadilino syndrome Meckel syndrome obsolete Opitz-GBBB syndrome Ogden syndrome iridogoniodysgenesis syndrome cone dystrophy achalasia microcephaly syndrome cerebral creatine deficiency syndrome 1 Kahrizi syndrome temtamy preaxial brachydactyly syndrome Stargardt disease obsolete Matthew-Wood syndrome orotic aciduria Perrault syndrome Marshall-Smith syndrome Caroli disease pancreatic agenesis Koolen de Vries syndrome spinocerebellar ataxia type 5 infantile cerebellar-retinal degeneration Townes-Brocks syndrome spastic ataxia 4 spastic ataxia 7 Charlevoix-Saguenay spastic ataxia autosomal recessive cerebellar ataxia spinocerebellar ataxia type 1 spinocerebellar ataxia type 4 Hirata disease Kartagener syndrome monogenic disease mesocestoidiasis obsolete genetic disorder obsolete peripheral dysostosis lacrimoauriculodentodigital syndrome 1 Danon disease Frasier syndrome Usher syndrome familial partial lipodystrophy Farber lipogranulomatosis erythrokeratodermia variabilis Donohue syndrome Alstrom syndrome Netherton syndrome Gamstorp-Wohlfart syndrome nonphotosensitive trichothiodystrophy 4 posterior polar cataract Charcot-Marie-Tooth disease type 1 Charcot-Marie-Tooth disease type 2 Charcot-Marie-Tooth disease type 3 hypermethioninemia obsolete Saldino-Noonan syndrome obsolete Majewski syndrome Walker-Warburg syndrome West syndrome congenital disorder of glycosylation type II 2-hydroxyglutaric aciduria

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.